Eiger Biopharmaceuticals招募了第一位接受丁型肝炎治疗的患者

StephenW

Eiger Biopharmaceuticals enrolls first patient in trial for hepatitis D therapy
August 7, 2018

Eiger BioPharmaceuticals announced the first patient enrollment in its phase 2 study of combination interferon lambda with ritonavir-boosted lonafarnib, according to a press release.

“Eiger is developing lonafarnib-based regimens alone and in combination with pegylated interferon-alfa as the first potential therapies for the treatment of HDV, and this program is advancing into phase 3 with the international, multi-center, D-LIVR study, planned to begin later this year,” David Apelian, MD, PhD, MBA, chief operating oficer and executive medical officer of Eiger, said in the press release. “Lambda represents a potentially better tolerated interferon for the treatment of HDV, and our goal is to expand future therapeutic options for patients with HDV infection.”


The LIFT (Lambda InterFeron combo-Therapy) open-label phase 2 study was designed to evaluate the efficacy and tolerability of Lambda (pegylated interferon-lambda, Eiger BioPharmaceuticals) with combination of the company’s lonafarnib and AbbVie’s Norvir (ritonavir) in approximately 26 patients with HDV for 24 weeks.

Eiger recently received notice of allowance from the U.S. Patent and Trademark Office for a patent claim on ritonavir-boosted lonafarnib for the treatment of hepatitis D.

“We have previously demonstrated in multiple studies at [National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)] that lonafarnib and ritonavir-boosted lonafarnib can decrease HDV RNA viral load in patients infected with HDV,” Christopher Koh, MD, principal investigator at the NIDDK, said in the release. “We have enrolled the first patient in LIFT, and now look forward to studying pegylated interferon lambda in combination with ritonavir-boosted lonafarnib."

Reference: www.eigerbio.com

StephenW

Eiger Biopharmaceuticals招募了第一位接受丁型肝炎治疗的患者
2018年8月7日

根据一份新闻稿，Eiger BioPharmaceuticals宣布第一项患者参加了第2期干扰素λ与利托那韦增强的lonafarnib联合治疗。

“Eiger正在开发基于lonafarnib的治疗方案，并与聚乙二醇化干扰素α联合作为治疗HDV的第一种潜在疗法，该计划正在进入国际多中心D-LIVR研究的第3阶段，计划进行今年晚些时候开始，“医学博士，医学博士，MBA，艾格的首席执行官兼执行医疗官员David Apelian在新闻发布会上说。 “Lambda代表了一种可能更好的耐受干扰素治疗HDV，我们的目标是扩大HDV感染患者未来的治疗选择。”


LIFT（Lambda InterFeron组合疗法）开放标签2期研究旨在评估Lambda（聚乙二醇化干扰素-λ，Eiger BioPharmaceuticals）与约26名患者联合使用该公司的lonafarnib和AbbVie的Norvir（利托那韦）的疗效和耐受性HDV持续24周。

Eiger最近收到了美国专利商标局关于利托那韦增强的lonafarnib治疗丁型肝炎的专利申请的通知。

“我们之前已经在[国家糖尿病和消化和肾脏疾病研究所（NIDDK）]的多项研究中证实，lonafarnib和利托那韦增强的lonafarnib可降低感染HDV的患者的HDV RNA病毒载量，”Christopher Koh，MD，首席研究员在NIDDK，在发布会上说。 “我们已经招募了LIFT的第一位患者，现在期待研究聚乙二醇干扰素λ与利托那韦增强的lonafarnib联合使用。”

参考：www.eigerbio.com